Vnitr Lek 2017, 63(3):194-198 | DOI: 10.36290/vnl.2017.040

The role of cardiovascular magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Part I

Martin Pleva1,2,*, Júlia Borová1, Ilona Plevová3, Jaroslav Januška1, Margita Belicová4
1 Komplexní kardiovaskulární centrum Nemocnice Podlesí a.s., Třinec
2 Vaskulární centrum Vítkovické nemocnice, a.s., Ostrava
3 Ústav ošetřovatelství a porodní asistence LF OU, Ostrava
4 I. interná klinika JLF UK a UNM, Martin, Slovenská republika

Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy in our population. The diagnosis of this disease is based on imaging methods, mainly echocardiography. Cardiac magnetic resonance offers more accurate and detailed information about the disease than echocardiography. Development of this method has become a standard part of the diagnostic algorithm. In the first part of review, the authors analyze the potential and significance of cardiac magnetic resonance in the diagnosis of hypertrophic cardiomyopathy.

Keywords: cardiac magnetic resonance; fibrosis; hypertrophic cardiomyopathy

Received: November 5, 2016; Accepted: March 13, 2017; Published: March 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pleva M, Borová J, Plevová I, Januška J, Belicová M. The role of cardiovascular magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Part I. Vnitr Lek. 2017;63(3):194-198. doi: 10.36290/vnl.2017.040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Maron BJ, Ommen SR, Semsarian C et al. Hypertrophic cardiomyopathy. Present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014; 64(1): 83-99. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2014.05.003>. Go to original source... Go to PubMed...
    2. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010; 121(3): 445-456. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.878579>. Erratum in Circulation 2010; 122(1): e7. Go to original source... Go to PubMed...
    3. Elliott PM, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008; 29(2): 270-276. Go to original source... Go to PubMed...
    4. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014; 35(39): 2733-2779. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu284>. Go to original source... Go to PubMed...
    5. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2012; 14: 13. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-14-13>. Go to original source... Go to PubMed...
    6. Germans T, Nijveldt R, Brouwer WP et al. The role of cardiac magnetic resonance imaging in differentiating the underlying causes of left ventricular hypertrophy. Neth Heart J 2010; 18(3): 135-143. Go to original source... Go to PubMed...
    7. Rickers C, Wilke NM, Jerosch-Herold M et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112(6): 855-861. Go to original source... Go to PubMed...
    8. Pleva M, Ouředníček P. MRI srdce. Praktické využití z pohledu kardiologa. Grada Publishing: Praha 2012. ISBN 978-80-247-3931-1.
    9. Stewart GA, Foster J, Cowan M et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999; 56(6): 2248-2253. Go to original source... Go to PubMed...
    10. Olivotto I, Maron MS, Autore C et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 52(7): 559-566. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.04.047>. Go to original source... Go to PubMed...
    11. Maron MS, Maron BJ, Harrigan C et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009; 54(3): 220-228. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.05.006>. Go to original source... Go to PubMed...
    12. Maron MS, Olivotto I, Harrigan CJ et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011; 124(1): 40-47. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.985812>. Go to original source... Go to PubMed...
    13. Kwon DH, Setser RM, Thamilarasan M et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart 2008; 94(10): 1295-1301. Go to original source... Go to PubMed...
    14. Harrigan CJ, Appelbaum E, Maron BJ et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008; 101(5): 668-673. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2007.10.032>. Go to original source... Go to PubMed...
    15. Veselka J, Linhartová K, Zemánek D. Kardiomyopatie. Galén: Praha 2009. ISBN 978-80-7262-640-3.
    16. To AC, Dhillon A, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2011; 4(10): 1123-1237. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2011.06.022>. Go to original source... Go to PubMed...
    17. Moon JC, McKenna WJ. Myocardial crypts: a prephenotypic marker of hypertrophic cardiomyopathy? Circ Cardiovasc Imaging 2012; 5(4): 431-432. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCIMAGING.112.975888>. Go to original source... Go to PubMed...
    18. Maron MS, Rowin EJ, Lin D et al. Prevalence and clinical profil of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2012; 5(4): 441-447. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCIMAGING.112.972760>. Go to original source... Go to PubMed...
    19. Germans T, Wilde AAM, Dijkmans PA et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006; 48(12): 2518-2523. Go to original source... Go to PubMed...
    20. Child N, Muhr T, Sammut E et al. Prevalence of myocardial crypts in a large retrospective cohort study by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2014; 16: 66. Dostupné z DOI: <http://dx.doi.org/10.1186/s12968-014-0066-0>. Go to original source... Go to PubMed...
    21. Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part I, MRI appearances. AJR Am J Roentgenol 2007; 189(6): 1335-1343. Go to original source... Go to PubMed...
    22. Maron MS, Hauser TH, Dubrow E et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol 2007; 100(8): 1293-1298. Go to original source... Go to PubMed...
    23. Maron MS. Contrast-enhanced CMR in HCM. What lies behind the bright light of LGE and why it now matters. JACC Cardiovasc Imaging 2013; 6(5): 597-599. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2012.10.028>. Go to original source... Go to PubMed...
    24. Moravsky G, Ofek E, Rakowski H et al. Myocardial fibrosis in hypertrophic cardiomyopathy. Accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 2013; 6(5): 587-596. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2012.09.018>. Go to original source... Go to PubMed...
    25. Noureldin RA, Liu S, Nacif MS et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012; 14: 17. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-14-17>. Go to original source... Go to PubMed...
    26. Adabag AS, Maron BJ, Appelbaum E et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51(14): 1369-1374. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2007.11.071>. Go to original source... Go to PubMed...
    27. Ismail TF, Jabbour A, Gulati A et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 2014; 100(23): 1851-1858. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2013-305471>. Go to original source... Go to PubMed...
    28. Olivotto I, Maron BJ, Appelbaum E et al. Olivotto I, Maron BJ, Appelbaum E et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010; 106(2): 261-267. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2010.03.020>. Go to original source... Go to PubMed...
    29. Chan RH, Maron BJ, Olivotto I et al. Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2015; 17(Suppl 1): Q59. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-17-S1-Q59>. Go to original source...
    30. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrofic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58(25): e212-e260. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.06.011>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.